Overall, higher PARP1 selectivity over PARP2, durable DNA trapping capability, improved PK and PD properties, favorable tumor‒to‒plasma distribution ratios, and potent antitumor activity show promise for enhancing the clinical efficacy of VB15010 and reducing hematological toxicity in patients [113]. Here, PARP1 is linked to neoplasm.